Result of General Meeting & Fundraising Completion

4 January 2021

THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN SENSYNE HEALTH PLC IN ANY JURISDICTION IN WHICH ANY SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL.

Sensyne Health plc

("Sensyne Health" or the "Company")

Result of General Meeting
and
Completion of Fundraising and Strategic Collaboration with Phesi

Oxford, UK - 4 January 2021: Sensyne Health plc (AIM: SENS), the UK clinical AI company, announces that at the General Meeting held earlier today, the Resolutions proposed were duly passed by shareholders. The General Meeting was held to approve the proposed Placing, Subscription and Open Offer to raise £27.5 million through the issuance of 30,513,341 New Shares in the Company. In addition, the passing of the Resolutions means that the Strategic Collaboration between Sensyne Health and Phesi Inc, a US based specialist clinical trials data company, will become effective on 5 January 2021. 

The full text of the Resolutions can be found in the Notice of General Meeting set out in the shareholder circular published by the Company on 14 December 2020 which is available on the Company's website www.sensynehealth.com.

It is expected that Admission of the New Shares will become effective at 8.00 a.m. on 5 January 2021. Following Admission, the Company will have 159,084,855 Ordinary Shares of 10p in issue each with equal voting rights. No shares are held in treasury.  

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement of the Fundraising made by the Company on 08 December 2020.

For further information, please contact:

 About Sensyne

Sensyne Health (AIM: SENS) is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS guidelines, UK data protection law and applicable regulatory guidance. Sensyne Health is based in the Schrödinger Building in Oxford Science Park. For more information, please visit: www.sensynehealth.com